AVDL250117P30000
- 15.78
- 0.000.00%
Avadel Pharmaceuticals Newsroom
UBS Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $22
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Avadel Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $25
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham
Avadel Pharmaceuticals Analyst Ratings
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Avadel Pharmaceuticals Is Maintained at Outperform by Oppenheimer
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $27
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Raises Target Price to $30
Avadel Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $27
Avadel Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Craig-Hallum Remains a Buy on Avadel Pharmaceuticals (AVDL)
Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $29
Analysts Are Bullish on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Rani Therapeutics Holdings (RANI)
Avadel Pharmaceuticals Analyst Ratings